Kennedy Capital Management LLC Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Kennedy Capital Management LLC boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 7.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,713 shares of the company’s stock after buying an additional 928 shares during the period. Kennedy Capital Management LLC’s holdings in Janux Therapeutics were worth $681,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. FMR LLC raised its stake in shares of Janux Therapeutics by 10.8% during the 4th quarter. FMR LLC now owns 8,669,941 shares of the company’s stock valued at $464,189,000 after purchasing an additional 845,266 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Janux Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company’s stock worth $114,379,000 after buying an additional 288,402 shares in the last quarter. Geode Capital Management LLC grew its stake in Janux Therapeutics by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 714,956 shares of the company’s stock valued at $38,288,000 after acquiring an additional 52,362 shares in the last quarter. Wellington Management Group LLP increased its holdings in Janux Therapeutics by 3,592.9% during the 4th quarter. Wellington Management Group LLP now owns 535,396 shares of the company’s stock worth $28,665,000 after acquiring an additional 520,898 shares during the period. Finally, Franklin Resources Inc. lifted its stake in Janux Therapeutics by 2,519.6% in the 4th quarter. Franklin Resources Inc. now owns 497,287 shares of the company’s stock worth $26,625,000 after purchasing an additional 478,304 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Up 0.5 %

NASDAQ JANX opened at $28.95 on Tuesday. The firm has a market cap of $1.71 billion, a PE ratio of -24.74 and a beta of 3.27. Janux Therapeutics, Inc. has a 1-year low of $22.52 and a 1-year high of $71.71. The stock has a 50-day moving average of $31.41 and a 200-day moving average of $44.02.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. acquired 110,206 shares of Janux Therapeutics stock in a transaction on Friday, March 7th. The shares were acquired at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. This trade represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders own 29.40% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Scotiabank decreased their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Wedbush reissued an “outperform” rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Janux Therapeutics has an average rating of “Buy” and an average target price of $92.44.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.